1 week Ago By Defense World Staff
Orion Portfolio Solutions LLC lowered its stake in QuidelOrtho Co. (NASDAQ:QDEL – Free Report) by 9.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission.
The fund owned 18,179 shares of the company’s stock after selling 1,899 shares during the period. Orion Portfolio Solutions LLC’s holdings in QuidelOrtho were worth $810,000 as of its most recent filing with the Securities & Exchange Commission. A number of other large investors have also added to or reduced their stakes in QDEL.
Pictet Asset Management Holding SA boosted its stake in QuidelOrtho by 39.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 9,588 shares of the company’s stock worth $427,000 after purchasing an additional 2,721 shares in the last quarter.
Norges Bank bought a new stake in shares of QuidelOrtho during the fourth quarter valued at approximately $34,171,000. JPMorgan Chase & Co. raised its holdings in QuidelOrtho by 14.
0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,406,654 shares of the company’s stock worth $62,666,000 after acquiring an additional 173,174 shares during the last quarter.
WINTON GROUP Ltd lifted its position in QuidelOrtho by 23.4% in the 4th quarter. WINTON GROUP Ltd now owns 169,961 shares of the company’s stock valued at $7,572,000 after acquiring an additional 32,222 shares in the last quarter.
Finally, Segall Bryant & Hamill LLC boosted its stake in QuidelOrtho by 143.9% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,046,649 shares of the company’s stock valued at $46,628,000 after purchasing an additional 617,592 shares during the last quarter.
Hedge funds and other institutional investors own 99.00% of the company’s stock. QuidelOrtho Price PerformanceShares of NASDAQ:QDEL opened at $28.
13 on Monday. The firm’s 50 day moving average price is $39.06 and its 200-day moving average price is $40.
94. The company has a quick ratio of 0.69, a current ratio of 1.
22 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.
90 billion, a PE ratio of -0.93 and a beta of 0.43.
QuidelOrtho Co. has a twelve month low of $26.84 and a twelve month high of $49.
45. QuidelOrtho (NASDAQ:QDEL – Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.
63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44).
QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%.
Equities research analysts expect that QuidelOrtho Co. will post 2.3 EPS for the current year.
Analysts Set New Price TargetsA number of analysts have commented on QDEL shares. Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $44.00 to $50.
00 in a research note on Wednesday, December 11th. StockNews.com lowered QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th.
Jefferies Financial Group initiated coverage on shares of QuidelOrtho in a report on Tuesday, December 10th. They set a “hold” rating and a $43.00 price target on the stock.
Royal Bank of Canada decreased their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th.
Finally, UBS Group raised their target price on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th.
Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $51.20.
Check Out Our Latest Stock Report on QDELQuidelOrtho Company Profile (Free Report)QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
Read MoreFive stocks we like better than QuidelOrthoStock Average Calculator Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?What Are Dividend Contenders? Investing in Dividend ContendersDisney 2025 Shareholders: Major Updates for InvestorsConsumer Discretionary Stocks ExplainedAdvance Auto Parts Stock: A Classic Rebound Play in the Making.
